The $1.8 trillion global pain management market is dominated by opioids and pharmaceuticals that often lead to dependency, side effects, and limited long-term effectiveness. Millions of people suffering from chronic pain lack accessible, drug-free alternatives, creating an urgent need for innovation in the field.
This company has developed a clinically validated, non-invasive neurotechnology that targets the brain’s maladaptive pain signals—providing measurable relief without medication. Unlike conventional treatments that mask symptoms, this AI-powered neurofeedback system rewires the brain’s pain response, offering a scalable, home-based solution that eliminates the need for costly clinic visits or pharmaceutical dependency.
With regulatory approvals secured in key markets including the US, UK, and New Zealand, strategic distribution partnerships, and a first-mover advantage in AI-driven pain management, the company is positioned to disrupt the industry and transform the standard of care.
Currently raising $10M to scale production, accelerate commercialization, and expand into adjacent markets like mental health, this is a high-impact opportunity to invest in the future of neurotechnology and digital therapeutics.
